New drug AK112 takes on standard immunotherapy in lung cancer showdown
NCT ID NCT05499390
First seen Mar 12, 2026 · Last updated May 08, 2026 · Updated 10 times
Summary
This phase 3 trial tests whether a new drug called AK112 works better than the standard immunotherapy pembrolizumab for people with advanced non-small cell lung cancer that has a specific marker (PD-L1). About 398 participants with stage IIIB/C or IV lung cancer will receive either AK112 or pembrolizumab as their first treatment. The main goal is to see which drug delays cancer growth longer, while also monitoring side effects and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.